MedDataX Logo

Prospective Assessment of nProfiler® 1 on Prognosis and Chemotherapy Response for Gastric Cancer

NCT ID: NCT04487717

Last Updated: 2024-12-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

581 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-07-29

Study Completion Date

2029-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prospective assessment of nProfiler® 1 predictive test on prognosis and chemotherapy response for resectable gastric cancer

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1. Background: According to Global Cancer Statistics of International Agency for Research on Cancer under World Health Organization, stomach cancer is the fifth most common cancer as there were over 1 million new cases in 2018 and the third leading cause of cancer death by 783,000 people are estimated to die of stomach cancer. In Korea, gastric cancer is the most frequent cancer in 13.3% of all cancer cases by the report of Korea Central Cancer Registry in 2018. Since 2010, adjuvant chemotherapy with advanced gastric cancer stage 2 and stage 3 patients following gastrectomy has become a standard treatment through clinical validation of increasing the patient's survival rate. However, even in the second and third stages of the same stomach cancer, the biological properties may be different.
2. Purpose:

The nProfiler® 1 Stomach Cancer Assay is a molecular diagnostic test to predict the prognosis for patients with stage Ⅱ-Ⅲ advanced gastric cancer. This study will evaluate the clinical utility of nProfiler® 1 Stomach Cancer Assay by recruiting subjects from multi centers and observing the 5-year survival rates of Low risk, Intermediate risk, High risk according to gastric cancer prognostic molecular diagnostic test.
3. Study Procedure:

* Obtaining of informed consent form
* Review of provider's eligibility/ Sample preparation and delivery
* Sample criteria evaluation
* Subject enrollment
* Gastric cancer prognostic prediction molecular diagnostic test
* Prognostic group result report
* 5-yr survival follow-up
* Statistical analysis
4. Outcome Measures:

The following efficacy outcome measures will be assessed:

* Primary efficacy outcome measure

:High risk and low risk group's 5-yr Overall Survival(OS) rate
* Secondary efficacy outcome measure

* High risk and Low risk group's 3-yr Disease Free Survival(DFS) rate
* Intermediate risk group's 5-yr OS and 3-yr DFS rate
* Subgroup analysis : Adjuvant chemotherapy benefit of Low risk (5-yr OS rate, 3 yr DFS rate)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastric Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PREDICT cohort

Patients with pathologic stage II, III advanced gastric cancer

nProfiler I Stomach Cancer Assay Kit

Intervention Type DEVICE

nProfiler I Stomach Cancer Assay Kit (Novomics Co., Korea)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

nProfiler I Stomach Cancer Assay Kit

nProfiler I Stomach Cancer Assay Kit (Novomics Co., Korea)

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Sample providers criteria

* Male and female adult patients aged 19 years or over
* Patients with histologically confirmed gastric adenocarcinoma
* Patients with histologically confirmed stage Ⅱ or Ⅲ
* Patients who have undergone radical gastrectomy
* Patients who have not received neoadjuvant chemotherapy and radiotherapy
* Patients who have undergone a radical gastrectomy and who show no evidence of residual tumors as observed with the unaided eye or through a microscope
* Patients who have signed a written consent of the study and signed a human derived research agreement (Form 34)
2. Sample criteria

* The formalin-fixed paraffin-embedded (FFPE) tumor specimens in storage have a tumor amount of at least 20% and therefore can be tested.
* The quantity (not less than 400ng) and quality (A260/280 of not less than 1.8) of RNA are sufficient for analysis.

Exclusion Criteria

1. Sample providers criteria

* Male and female patients aged less than 19 years
* Patients with histologically not confirmed gastric adenocarcinoma
* Patients with histologically confirmed stage Ⅰ or Ⅳ
* Patients who have not undergone radical gastrectomy
* Patients who have received neoadjuvant chemotherapy or radiotherapy
* Patients with distant or peritoneal metastasis at the time of surgery or residual tumors after surgery
* Patients who have not signed the study's written consent and human derived research agreement (Form 34)
2. Sample criteria

* The FFPE tumor specimens in storage have a tumor amount of less than 20% and therefore cannot be tested
* The quantity and quality of RNA are not sufficient for analysis
Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Novomics. Co., Ltd.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Young-Woo Kim, MD., Ph.D.

Role: PRINCIPAL_INVESTIGATOR

National Cancer Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Novomics

Seoul, , South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NM-CTP-05

Identifier Type: -

Identifier Source: org_study_id